211 related articles for article (PubMed ID: 20664970)
1. Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer.
Wurster M; Ruoff A; Meisner C; Seeger H; Vogel U; Juhasz-Böss I; Solomayer E; Wallwiener D; Fehm T; Neubauer H
Oncol Rep; 2010 Sep; 24(3):653-9. PubMed ID: 20664970
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
3. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer.
Borgquist S; Holm C; Stendahl M; Anagnostaki L; Landberg G; Jirström K
J Clin Pathol; 2008 Feb; 61(2):197-203. PubMed ID: 18223096
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
5. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.
Vinayagam R; Sibson DR; Holcombe C; Aachi V; Davies MP
BMC Cancer; 2007 Jul; 7():131. PubMed ID: 17640362
[TBL] [Abstract][Full Text] [Related]
6. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
7. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
[TBL] [Abstract][Full Text] [Related]
8. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
9. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
10. Changes in tumour biological markers during primary systemic chemotherapy (PST).
Neubauer H; Gall C; Vogel U; Hornung R; Wallwiener D; Solomayer E; Fehm T
Anticancer Res; 2008; 28(3B):1797-804. PubMed ID: 18630463
[TBL] [Abstract][Full Text] [Related]
11. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
12. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
14. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR.
Green AR; Young P; Krivinskas S; Rakha EA; Claire Paish E; Powe DG; Ellis IO
Histopathology; 2009 Mar; 54(4):419-27. PubMed ID: 19309393
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients.
Cappelletti V; Celio L; Bajetta E; Allevi A; Longarini R; Miodini P; Villa R; Fabbri A; Mariani L; Giovanazzi R; Galante E; Greco M; Grazia Daidone M
Endocr Relat Cancer; 2004 Dec; 11(4):761-70. PubMed ID: 15613450
[TBL] [Abstract][Full Text] [Related]
16. Steroid hormone receptor expression in male breast cancer.
Murphy CE; Carder PJ; Lansdown MR; Speirs V
Eur J Surg Oncol; 2006 Feb; 32(1):44-7. PubMed ID: 16260112
[TBL] [Abstract][Full Text] [Related]
17. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
Kulka J; Tokés AM; Tóth AI; Szász AM; Farkas A; Borka K; Járay B; Székely E; Istók R; Lotz G; Madaras L; Korompay A; Harsányi L; László Z; Rusz Z; Molnár BA; Molnár IA; Kenessey I; Szentmártoni G; Székely B; Dank M
Magy Onkol; 2009 Dec; 53(4):335-43. PubMed ID: 20071305
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
